Abstract library

85 results for "cancers".
#2992 The PanNENomics Project: A Call for an International Collaborative Effort Built on the Success of the LungNENomics Project
Introduction: Neuroendocrine tumors are rare understudied diseases at the molecular level, especially those occurring in sites outside the lung and the gastrointestinal track. This lack of knowledge has strong implications for the clinical management of these diseases (Rindi et al. Mad Pathol 2018).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: PhD Lynnette Fernandez-Cuesta
#761 Use of Molecular Imaging to Differentiate Neuroendocrine Tumors from Other Synchronous Primary Cancers: A Case Series
Introduction: Approximately 22% of neuroendocrine tumors (NET) co-exist with other cancers.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: DR Vincent Cheung
Keywords: NET, synchronous, PET, Gallium, FDG
#1112 Second Primary Malignancies in Patients with Neuroendocrine Tumors
Introduction: Numerous studies have demonstrated an elevated incidence of second primary malignancies (SPM) in patients with neuroendocrine tumours (NET).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Ashley Clift
#2024 Metachronous Primary Cancers in Neuroendocrine Tumor Patients
Introduction: Historically there has been an association between neuroendocrine tumours (NETs) and second primary cancers (Stronge et al 2014). However, this has not been well characterised.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#306 The Risk of Metachronous Cancers In Patients with Small Intestinal Carcinoid Tumors
Introduction: Small intestinal carcinoids (SIC) are the most common small bowel malignancies. No population-based study has examined the risk for, and prognosis of, metachronous cancers and SICs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Michelle Kim
Authors: Amin S, Warner R R, Itzkowitz S, Kim M, ...
#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers
Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Ulrich M. Lauer
#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers
Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christine Merkel
#537 Survival of Patients with Neuroendocrine Cancers in Ontario Over the Last 15 Years
Introduction: There has been an increased incidence of neuroendocrine tumors (NETs) in Ontario, Canada, over the last 15 years but little is known about trends in survival.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Cukier M, Liu N, Saskin R, ...
Keywords: survival
#1189 European Information Network on Rare Cancers (RARECAREnet)
Introduction: NETs are considered as a rare cancer. Because of the complexity and the different disciplines involved, a multidisciplinary approach is desirable. The referral to centres of expertise (CoE) is indicated as the optimal strategy for effective management.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MSc. Jan Maarten Van der Zwan
Keywords: Registry
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill